Alector, Inc. (ALEC)
NASDAQ: ALEC · Real-Time Price · USD
1.780
-0.030 (-1.66%)
Oct 7, 2026, 11:25 AM EDT - Market open
Alector Revenue
Alector had revenue of $3.32M in the quarter ending June 30, 2026, a decrease of -57.84%. This brings the company's revenue in the last twelve months to $13.86M, down -82.91% year-over-year. In the year 2025, Alector had annual revenue of $21.05M, down -79.07%.
Revenue (ttm)
$13.86M
Revenue Growth
-82.91%
P/S Ratio
14.58
Revenue / Employee
$134,592
Employees
103
Market Cap
198.75M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 21.05M | -79.51M | -79.07% |
| Dec 31, 2024 | 100.56M | 3.50M | 3.60% |
| Dec 31, 2023 | 97.06M | -36.56M | -27.36% |
| Dec 31, 2022 | 133.62M | -73.47M | -35.48% |
| Dec 31, 2021 | 207.09M | 185.99M | 881.54% |
| Dec 31, 2020 | 21.10M | -121.00K | -0.57% |
| Dec 31, 2019 | 21.22M | -6.46M | -23.33% |
| Dec 31, 2018 | 27.68M | 23.94M | 641.02% |
| Dec 31, 2017 | 3.74M | 3.32M | 797.84% |
| Dec 31, 2016 | 416.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Protalix BioTherapeutics | 80.62M |
| Compugen | 74.00M |
| ProQR Therapeutics | 21.05M |
| Keros Therapeutics | 15.01M |
| Lineage Cell Therapeutics | 13.08M |
| Whitehawk Therapeutics | 7.15M |
| Cartesian Therapeutics | 1.48M |
| Lyell Immunopharma | 27.00K |
ALEC News
- Just now - Alector Press release: Investor update - Filings
- 1 day ago - Alector price target raised to $3 from $2 at Morgan Stanley - TheFly
- 2 days ago - Why is Alector Stock (ALEC) 60% Higher Today? - TipRanks
- 2 days ago - Alector soars as Roche licenses Parkinson's therapy for up to $1.27 billion - Reuters
- 2 days ago - Alector enters exclusive AL050 global licensing agreement with Genentech - TheFly
- 2 days ago - Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson's Disease and Other Neurodegenerative Diseases - GlobeNewsWire
- 22 days ago - Alector Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 26 days ago - Alector Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts